Ellis M N, Lobe D C, Spector T
Division of Virology, Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.
Antimicrob Agents Chemother. 1989 Oct;33(10):1691-6. doi: 10.1128/AAC.33.10.1691.
Clinical effects of the administration of a combination of acyclovir (ACV) and compound A1110U (a 2-acetylpyridine thiocarbonothiohydrazone inactivator of herpes simplex virus [HSV] ribonucleotide reductase) on the development of herpetic skin lesions were studied in athymic and hairless mice infected intracutaneously with different HSV type 1 (HSV-1) strains. ACV was administered topically (5%) or orally (5 mg/ml), while A1110U was applied topically (3%). In all but one experiment, the effect of combination therapy was greater than that calculated for the sum of the individual drug effects in limiting the development of herpetic skin lesions in mice. In several experiments, combination therapy totally eliminated all signs of infection. This synergistic chemotherapeutic efficacy was evident in infections caused by ACV-susceptible as well as several ACV-resistant HSV-1 strains. These results indicate that this combination therapy may provide a significant improvement in clinical responses over single-agent topical therapy.
在经皮内注射不同1型单纯疱疹病毒（HSV-1）毒株感染的无胸腺无毛小鼠中，研究了阿昔洛韦（ACV）与化合物A1110U（一种单纯疱疹病毒[HSV]核糖核苷酸还原酶的2-乙酰吡啶硫代碳酰腙灭活剂）联合给药对疱疹性皮肤损伤发展的临床效果。ACV通过局部（5%）或口服（5mg/ml）给药，而A1110U通过局部（3%）给药。除一项实验外，在所有实验中，联合治疗在限制小鼠疱疹性皮肤损伤发展方面的效果均大于单独药物效应之和的计算值。在几项实验中，联合治疗完全消除了所有感染迹象。这种协同化疗效果在由ACV敏感以及几种ACV耐药的HSV-1毒株引起的感染中均很明显。这些结果表明，与单药局部治疗相比，这种联合治疗可能会显著改善临床反应。
